Our pipeline is comprised of innovative therapeutic product candidates we believe have the potential for value creation using our partnership-enabled business model.
Our flagship product candidates, BackBeat CNT (AVIM therapy) and Virtue SAB, exemplify key criteria that characterize innovations optimized for strategic partnerships:
*Plan to leverage existing coronary in-stent restenosis (ISR) data to support potential Pivotal Study; Virtue SAB has received Breakthrough Device Designation for: 1The balloon dilatation of the stenotic portion (up to 26 mm length) of a stented coronary artery that is 2.25 to 4.0 mm in diameter, for the purpose of improving lumen diameter; 2The balloon dilation of the de novo stenotic portion (up to 26mm in lesion length) of a native coronary artery of 2.0 mm to 2.5 mm in diameter (small coronary arteries), for the purpose of improving lumen diameter; 3The balloon dilatation of the stenotic portion (up to 18 mm length) of an infrapopliteal artery (P-3 segment or distal, below the knee, with reference vessel diameter (RVD) 2.25 - 4.0 mm), for the purpose of improving lumen diameter.
Virtue® SAB is investigational and not commercially approved.
BackBeat CNT™ (also known as AVIM therapy) is investigational and not commercially approved.
© 2024 Orchestra BioMed Inc. Virtue®, BackBeat CNT™ FreeHold Duo®, FreeHold Trio® and Orchestra BioMed™ are trademarks of Orchestra BioMed.
All other trademarks are trademarks of their respective owners.
SM-0020 Rev 01